The Bear Cave #341
BMF Reports argues SELLAS Life Sciences (SLS) is overvalued due to unclear Phase 3 trial data, predicting 76% downside if it fails. Fugazi Research claims TEN Holdings (XHLD) is a pump-and-dump scheme. A Value Investors’ Club author warns Charter Communications (CHTR) faces debt and competition risks. Notable executive departures include D-Wave Quantum (QBTS), Azenta (AZTA), Amrize (AMRZ), GE Vernova (GEV), and Tesla (TSLA).



